Drugmaker Moderna has shipped its first batch of a possible coronavirus vaccine for humans to government researchers for testing.
Shares of the biotech company soared early Tuesday, a day after the company said it sent vials to the National Institute of Allergy and Infectious Diseases for early-stage testing in the United States.
More than 80,000 people have been infected globally from the viral outbreak that began late last year in China. A total of 35 cases have been reported in the United States.
Get weekly health news
More than 2,600 people have died from the virus in mainland China, including one U.S. citizen.
- Ontario man fighting Stage 4 cancer seeking answers on out-of-country coverage denial
- Doctor warns of ‘cancer tsunami’ as WHO projects sharp rise in cases by 2050
- Can a blood test tell if cancer is returning? Research is underway
- Can a blood test tell patients if their cancer is coming back? Researchers are on it
Shares of Cambridge, Massachusetts-based Moderna Inc. jumped nearly 16%, or $2.92, to $21.51 in premarket trading.
The stock started trading in late 2018 and set an all-time high price of $29.79 last April, according to FactSet.
Comments
Want to discuss? Please read our Commenting Policy first.